The Zurich based startup ZuriMED, specialising in orthopaedic biomechanics, has earned the Innosuisse certificate, thanks to its revolutionary device for ligament reconstruction. The company\u2019s Bone-Tendon-Bone (BTB)-Converter\u2122 is currently undergoing a clinical trial.<\/p>\n\n\n\n
Founded in 2015, ZuriMED<\/a> is developing a device for surgical knee ligament reconstruction, the BTB-Converter\u2122. The idea behind the new surgical technique it to effectively convert a less painful hamstring autograft (a patient\u2019s own tissue), or any other flexible graft, into a higher performance BTB-like graft. According to Xiang Li, Co-founder and CEO of ZuriMED, there has been a change from the original design in the product development. He says, \u201cDue to the EU regulatory environment transition, our original strategy of having a complete, preassembled BTB-Conversion-Kit\u2122 has changed: we would now have two separate implants, which could be assembled during surgery.\u201d<\/p>\n\n\n\n The first component of the kit, the BTB-Converter\u2122 is currently under clinical trial at University Hospital Balgrist, which started in 2017, and is scheduled to complete by early 2021. The second component, the product VariLoop\u2122 is expected to enter into clinical trial next year.\u201d<\/p>\n\n\n\n